ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer

NCT07423611 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

388

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Aromatase inhibitor (± ovarian suppression) plus Ribociclib
DRUG: 4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy

Sponsor

Fudan University